FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...

Researchers presented an exploratory analysis comparing OCT biomarkers in a Phase 1b study of ONL1204 in patients with ...